New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Thursday, November 12, 2026

Back to the front page

Looking Back at Another Successful Thesis

DoubleU Games raised its all-cash tender offer for DoubleDown Interactive minority holders to $16.25 per ADS from $11.25 after net cash made the earlier bid untenable.

From X

Convequity on X

More $NVDA chips could end up going to SpaceX and other buyers that can borrow at investment-grade rates, leaving neoclouds with fewer chips than they need. SpaceX's planned $40bn chip borrowing shows why. The deal: $SPCX is in early talks for about $10bn of bank loans and $30bn of investment-grade debt, led by Apollo, with Pimco also in talks. It would close in 2027, and the talks could still fall apart. The comparison: in December, Apollo lent about $3.5bn to fund xAI's Colossus 2 chips through a separate company set up just for that deal. The interest rate was about 10% a year. xAI is now part of SpaceX. Investment-grade debt usually costs much less. US investment-grade corporate bonds yield around 6% on average today. The rate on the new $30bn has not been reported, so we don't know the exact saving yet. Why it could be cheaper: lenders would be relying on SpaceX's launch and Starlink businesses to repay, not only on the chips. That is the real financial payoff of putting xAI inside SpaceX. Most GPU buyers can't borrow like that. $CRWV is rated junk (Moody's Ba3, Fitch BB-) and pays 9.25% on its 2030 bonds. Standalone AI labs have no public credit ratings that we could find. Not every neocloud pays up. $NBIS has a GPU loan at a floating benchmark rate plus 2.5%, against CoreWeave's plus 5.5%. Our view: the debate on X is whether this proves AI demand or shows too much leverage. We think the bigger point is cost of capital. When chips are scarce, the buyer that borrows most cheaply can pay for the most of them, and neoclouds paying junk-level rates get squeezed out.

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

Top Rebound Stocks for Nov’26

Texas Pacific Land's 50% selloff reflects faded data-center expectations, while its Permian royalty business generated $498 million of 2025…

ASML ($ASML) Deep Dive

ASML monopolizes EUV lithography, a critical tool for leading-edge chips, with production capacity stretched through 2028 and customer…

Peloton: Beyond The Bike

Peloton’s connected-fitness subscribers fell 9% year over year to 2.475 million, with another high-single-digit holiday decline forecast as…

MONOY · long

Monotaro CO LTD

MonotaRO, traded as MONOY in the U.S. and 3064 in Japan, is a Japanese MRO distributor recommended as a long.

ON THE TAPE with Guy Adami

Guy Adami discusses Nvidia, Anthropic's IPO prospects, energy, gold and the AI trade.

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.